Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug-induced QT Prolongation Atlas (DIQTA) for enhancing cardiotoxicity management
Authors
Keywords
Drug-induced prolongation of the QT interval, Torsades de pointes, Cardiotoxicity, Drug safety, Adverse drug reaction
Journal
DRUG DISCOVERY TODAY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-10-28
DOI
10.1016/j.drudis.2021.10.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Precision Dosing
- (2021) Kimberly Maxfield et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
- (2020) Joerg Herrmann Nature Reviews Cardiology
- COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
- (2020) Masataka Nishiga et al. Nature Reviews Cardiology
- Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association
- (2020) James E. Tisdale et al. CIRCULATION
- Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools
- (2020) Li Pang et al. ARCHIVES OF TOXICOLOGY
- A current understanding of drug-induced QT prolongation and its implications for anticancer therapy
- (2019) Dan M Roden CARDIOVASCULAR RESEARCH
- Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium
- (2018) Eunjung Park et al. BRITISH JOURNAL OF PHARMACOLOGY
- Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management
- (2018) Zhining Wen et al. DRUG DISCOVERY TODAY
- CredibleMeds.org: What does it offer?
- (2018) Raymond L. Woosley et al. TRENDS IN CARDIOVASCULAR MEDICINE
- DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans
- (2016) Minjun Chen et al. DRUG DISCOVERY TODAY
- Cardiovascular Toxic Effects of Targeted Cancer Therapies
- (2016) Javid J. Moslehi NEW ENGLAND JOURNAL OF MEDICINE
- The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress
- (2016) Thomas Colatsky et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Evaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordance
- (2015) Hugo M Vargas et al. BRITISH JOURNAL OF PHARMACOLOGY
- The SIDER database of drugs and side effects
- (2015) Michael Kuhn et al. NUCLEIC ACIDS RESEARCH
- Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report
- (2015) Stephanie K. Klein et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling
- (2014) Miriam J. Warnier et al. DRUG DISCOVERY TODAY
- Cardiac safety concerns for ondansetron, an antiemetic commonly used for nausea linked to cancer treatment and following anaesthesia
- (2013) Sheila A Doggrell et al. Expert Opinion On Drug Safety
- Assessing cardiovascular drug safety for clinical decision-making
- (2013) Raymond L. Woosley et al. Nature Reviews Cardiology
- FDA-approved drug labeling for the study of drug-induced liver injury
- (2011) Minjun Chen et al. DRUG DISCOVERY TODAY
- Cardiovascular pharmacogenomics and individualized drug therapy
- (2009) Naveen L. Pereira et al. Nature Reviews Cardiology
- Off-Label Use of Antiepileptic Drugs for the Treatment of Neonatal Seizures
- (2008) Faye S. Silverstein et al. PEDIATRIC NEUROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started